dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Miguel-Huguet, Bernat |
dc.contributor.author | Perez-Garcia, Jose Manuel |
dc.contributor.author | Páez, David |
dc.contributor.author | Guerrero‑Zotano, Angel |
dc.contributor.author | Garde-Noguera, Javier |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Sampayo-Cordero, Miguel |
dc.date.accessioned | 2021-10-29T11:44:33Z |
dc.date.available | 2021-10-29T11:44:33Z |
dc.date.issued | 2020-11-01 |
dc.identifier.citation | Sampayo-Cordero M, Miguel-Huguet B, Pérez-García J, Páez D, Guerrero-Zotano ÁL, Garde-Noguera J, et al. Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon’s design. Contemp Clin Trials Commun. 2020 Dec 1;20:100678. |
dc.identifier.issn | 2451-8654 |
dc.identifier.uri | https://hdl.handle.net/11351/6486 |
dc.description | No inferioritat; Fase II; Braç únic |
dc.description.sponsorship | Javier Cortés has received consulting and advisor fees from: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo and Erytech. In addition, Javier Cortés has received honorarias from: Roche, Novartis, Celgene, Eisai, Pfizer and Samsung. Add more, Javier Cortés has received research funding fees to the institution from Roche. Finally, Javier Cortés has stock options, patents and intellectual property from MedSIR. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Contemporary Clinical Trials Communications;20 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Medicina - Investigació |
dc.subject | Assaigs clínics |
dc.subject.mesh | Clinical Trials, Phase II as Topic |
dc.subject.mesh | /methods |
dc.subject.mesh | Research Design |
dc.subject.mesh | Neoplasms |
dc.title | Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.conctc.2020.100678 |
dc.subject.decs | ensayos clínicos en fase II como asunto |
dc.subject.decs | /métodos |
dc.subject.decs | diseño de la investigación |
dc.subject.decs | neoplasias |
dc.relation.publishversion | https://doi.org/10.1016/j.conctc.2020.100678 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Sampayo-Cordero M] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. [Miguel-Huguet B] Hospital Universitari de Bellvitge, L’Hospitalet, Barcelona, Spain. [Pérez-García J] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB, Institute of Oncology, QuironSalud Group, Barcelona and Madrid, Spain. [Páez D] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Guerrero-Zotano ÁL] Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center, Nashville, TN, USA. [Garde-Noguera J] Hospital Arnau de Vilanova, Valencia, Spain. [Cortés J] IOB, Institute of Oncology, QuironSalud Group, Barcelona and Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain |
dc.identifier.pmid | 33336109 |
dc.identifier.wos | 000603370200008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |